세계 바이오 포장 시장은 2024년에 19억 달러에 달했습니다. 2033년에는 40억 달러에 달할 것으로 예상되며, 예측 기간인 2025-2033년간 8.5%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.
헬스케어 바이오 포장은 의약품, 의료기기 및 헬스케어 산업을 위해 특별히 고안된 포장 솔루션으로, 기존의 플라스틱 및 기타 비생분해성 재료가 아닌 재생 가능한 생물 유래 재료로 만들어집니다. 이러한 포장 솔루션은 무균성, 장벽 보호, 내구성, 안전성과 같은 의료 분야의 엄격한 요구 사항을 충족하는 동시에 환경 친화적으로 개발되었습니다.
헬스케어 기업과 소비자들이 지속가능성의 중요성을 인식하고 포장재가 환경에 미치는 영향을 줄이기 위해 노력함에 따라 헬스케어 분야에서 바이오 포장에 대한 수요는 꾸준히 증가하고 있습니다. 예를 들어, 영국제약산업협회(ABPI)에 따르면, 탄소 발자국의 약 70-80%는 제조 과정에서 발생하며, 제조 과정의 설계자나 발명가들이 말하는 것처럼, 그 결정은 의약품의 유효기간 동안 영향을 미칩니다고 합니다.
성장 촉진요인과 억제요인
제약기업의 지속가능성 목표가 높아지고 있습니다.
제약사들의 지속가능성 목표가 높아짐에 따라 바이오 포장재 시장의 성장이 크게 촉진되고 있으며, 예측 기간 동안에도 시장을 주도할 것으로 예상됩니다. 주요 제약사들은 바이오 포장재를 사용하여 지속가능성을 기업 전략에 통합함으로써 순 배출량 제로 달성 및 탄소 발자국 감소와 같은 야심찬 지속가능성 목표를 설정하고 이를 달성하기 위해 노력하고 있습니다.
예를 들어, 2024년 10월, TekniPlex Healthcare는 최초의 ISCC PLUS 인증 바이오 PVC 컴파운드를 출시하여 의료용 포장재에 지속 가능한 대안을 제공했습니다. 이 새로운 소재는 튜브, 트레이용 필름, 파우치 및 기타 플라스틱 부품과 같은 의료용 포장 용도로 사용하도록 설계되어 환경 친화적인 대안을 제공합니다. 재생 가능 에너지로 만들어진 이 화합물은 CO2 배출량을 최대 90%까지 감소시켜 헬스케어 업계가 성능이나 안전성을 잃지 않으면서도 보다 지속 가능한 패키징을 구현할 수 있도록 돕습니다.
FDA 및 EMA와 같은 규제 기관은 헬스케어 분야에서 포장재의 환경 영향을 줄이기 위해 점점 더 많은 노력을 기울이고 있습니다. 이러한 규제는 ISO 준수와 같은 인증을 통해 바이오 포장재 사용을 포함한 지속 가능한 관행의 채택을 장려하고 있습니다.
예를 들어, 2024년 1월, 특수 지속 가능한 재료 솔루션 및 서비스를 제공하는 Avient Corporation은 Pharmapack 2024에서 바이오 폴리머 솔루션 포트폴리오를 소개할 것이라고 발표했습니다. 이 솔루션에는 바이오 폴리머 착색제 및 첨가제, 바이오 유래 열가소성 엘라스토머가 포함되며, TUV 라인란드(TUV Rheinland)의 ISO 14067 인증을 받은 Avient의 PCF 계산기를 통해 입증된 낮은 제품 탄소발자국(PCF) 값을 포함합니다. PCF) 값을 포함합니다.
엄격한 규제 요건
엄격한 규제 요건은 규정 준수를 복잡하게 만들고, 비용을 증가시키며, 시장 진입을 제한하는 장벽을 만들어 바이오 포장 시장의 성장을 크게 저해하고 있습니다. 이러한 규제는 의약품 포장의 중요한 특성으로 인해 헬스케어 분야에서 특히 엄격합니다. 바이오 포장은 의약품 응용 분야에서 안전성, 무균성 및 기능성과 관련하여 기존 재료와 마찬가지로 엄격한 기준을 충족해야 합니다. 여기에는 엄격한 생체 적합성 테스트, 안정성 테스트, 포장 내 약물 및 의료기기와의 호환성 등이 포함됩니다.
예를 들어, FDA는 바이오 포장재가 의약품, 의료기기 등 내용물에 악영향을 미치지 않는다는 것을 입증하기 위해 광범위한 테스트를 거치도록 요구하고 있습니다. 마찬가지로, 재료가 유해 물질을 용출하거나 의약품 및 의료기기의 무결성을 손상시키지 않아야 합니다. 이러한 요구 사항으로 인해 기존 플라스틱에 비해 바이오 재료의 규제 프로세스가 더 복잡하고 시간이 많이 걸립니다.
바이오 소재에 대한 규제 요건은 지역마다 크게 다르기 때문에 전 세계에 제품을 판매하려는 기업에게는 어려움이 있습니다. 예를 들어, 미국 FDA는 EU의 REACH(화학물질의 등록, 평가, 허가 및 제한) 규정과 다른 규정을 가지고 있습니다. 이러한 차이점은 바이오 포장재 제조업체가 국제 시장을 위해 제품을 표준화할 수 있는 능력을 복잡하게 만들고 있습니다.
The global bio based packaging market reached US$ 1.9 billion in 2024 and is expected to reach US$ 4.0 billion by 2033, growing at a CAGR of 8.5% during the forecast period 2025-2033.
Healthcare bio-based packaging refers to packaging solutions specifically designed for the pharmaceutical, medical device, and healthcare industries that are made from renewable, biologically sourced materials rather than conventional plastics or other non-biodegradable materials. These packaging solutions are developed to meet the stringent requirements of the healthcare sector, such as sterility, barrier protection, durability, and safety, while also being environmentally friendly.
The demand for bio-based packaging in the healthcare sector has been growing steadily as healthcare companies and consumers alike recognize the importance of sustainability and reducing the environmental impact of packaging materials. For instance, according to the Association of the British Pharmaceutical Industry (ABPI), about 70 to 80% of the carbon footprint sits in the manufacturing process and as the designers and inventors of those manufacturing processes say the decisions made will live with that product for the rest of its useful life as a medicine.
Market Dynamics: Drivers & Restraints
Rising sustainability goals of pharmaceutical companies
The rising sustainability goals of pharmaceutical companies are significantly driving the growth of the bio based packaging market and are expected to drive the market over the forecast period. Major pharmaceutical companies are setting ambitious sustainability targets, such as achieving net-zero emissions or reducing their carbon footprint by integrating sustainability into their corporate strategies by using bio-based packaging materials to meet these goals.
For instance, in October 2024, TekniPlex Healthcare unveiled the first ISCC PLUS-certified bio-based PVC compounds, offering a sustainable alternative for medical packaging. Its new materials are designed for use in medical packaging applications like tubing, films for trays, pouches, and other plastic components, providing eco-friendly options. Made with renewable energy, its compounds reduce CO2 emissions by up to 90%, helping the healthcare industry create more sustainable packaging without losing performance or safety.
Regulatory bodies, such as the FDA and EMA, are increasingly focused on reducing the environmental impact of packaging materials in the healthcare sector. These regulations encourage the adoption of sustainable practices, including the use of bio-based packaging materials by obtaining certifications like ISO compliance.
For instance, in January 2024, Avient Corporation, a leading provider of specialized and sustainable material solutions and services, announced it is highlighting its portfolio of bio-based polymer solutions at Pharmapack 2024. These solutions include bio-based polymer colorants and additives and bio-derived thermoplastic elastomers with lower product carbon footprint (PCF) values substantiated by Avient's PCF Calculator certified by TUV Rheinland for ISO 14067 compliance.
Stringent regulatory requirements
Stringent regulatory requirements significantly hamper the growth of the bio-based packaging market by creating barriers that complicate compliance, increase costs and limit market adoption. These regulations are particularly stringent in the healthcare sector due to the critical nature of pharmaceutical packaging. Bio-based packaging must meet the same rigorous standards as traditional materials for safety, sterility, and functionality in pharmaceutical applications. This includes rigorous biocompatibility tests, stability tests, and compatibility with the drug or medical device within the packaging.
For instance, the FDA requires bio-based packaging materials to undergo extensive testing to demonstrate that they do not interact negatively with the contents, such as pharmaceuticals or medical devices. Like, materials must not leach harmful substances or compromise the integrity of the drug or device. These requirements make the regulatory process more complex and time-consuming for bio-based materials compared to traditional plastics.
The regulatory requirements for bio-based materials vary significantly across different regions, creating challenges for companies looking to market their products globally. For instance, the FDA in the U.S. has different regulations compared to the EU's REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) regulations. These differences complicate the ability of bio-based packaging manufacturers to standardize their products for international markets.
The global bio based packaging market is segmented based on material type, application and region.
The biodegradable plastics segment is expected to dominate the bio based packaging market share
Biodegradable plastics are derived from renewable resources like corn starch, sugarcane, or polylactic acid (PLA). These materials can break down more easily in natural environments, reducing the overall environmental footprint compared to conventional plastics, which can persist for hundreds of years in landfills. Biodegradable plastics can be engineered to have similar properties to traditional plastics, such as durability, moisture resistance, and chemical resistance, making them suitable for packaging pharmaceuticals and medical devices.
For instance, in October 2024, Bayer launched a first-of-its-kind in the healthcare industry, polyethylene terephthalate (PET) blister packaging on its renowned brand, Aleve. Realized in partnership with pharma packaging specialist Liveo Research, this innovative solution reduces the carbon footprint of this packaging by 38% and marks a stride in environmental stewardship by eliminating the use of polyvinyl chloride (PVC).
Rising investments in biodegradable plastics are also increasing the market demand. For instance, in September 2024, Darmstadt-based BIOVOX announced the successful closing of its €2.2 million seed round. The round was led by High-Tech Grunderfonds (HTGF) with significant participation from Beteiligungs-Managementgesellschaft Hessen mbH (BMH) and a group of existing and new investors including Auxxo, Otto Braun, Petra Worwag and Katharina Klohe as well members of the business angel club better ventures and Business Angels FrankfurtRheinMain. The investment will enable BIOVOX to accelerate the development and production of its portfolio of innovative bioplastic solutions designed to revolutionize the healthcare industry.
North America is expected to hold a significant position in the bio based packaging market share
North America, particularly the United States and Canada, has a strong regulatory framework that encourages the adoption of sustainable packaging materials in the healthcare sector. The US FDA and Canadian regulatory bodies are pushing for more sustainable solutions to reduce the environmental impact of pharmaceutical packaging.
For instance, the FDA has issued guidance on the use of environmentally friendly packaging materials, including bio-based plastics, to ensure the safety and efficacy of pharmaceuticals. The directive is aimed at promoting packaging that is not only effective in protecting products but also sustainable.
In North America, there is a growing consumer preference for environmentally friendly products, which influences pharmaceutical companies to seek sustainable packaging solutions. Consumers are becoming more aware of the environmental impact of packaging materials and are demanding more eco-friendly options. This trend is particularly strong among younger demographics, who are more likely to choose sustainable products. For instance, according to the survey conducted by Accenture found that 83% of US consumers believe it's important for companies to design products that are environmentally friendly.
Asia-Pacific is growing at the fastest pace in the bio based packaging market
The Asia-Pacific region is witnessing significant economic growth, especially in countries like China, India, and Japan. This economic development is leading to an increased demand for healthcare products, which in turn drives the need for sustainable packaging solutions. As disposable incomes rise and urbanization accelerates, consumers are becoming more aware of the environmental impact of packaging and are increasingly demanding eco-friendly alternatives.
For instance, in China, the healthcare packaging market is expanding rapidly due to an aging population and increased healthcare spending. This growth is prompting the adoption of bio-based packaging to meet the demands of the pharmaceutical industry, which is under pressure to reduce waste and comply with stricter environmental regulations.
Major pharmaceutical companies in the APAC region are setting ambitious sustainability targets and are actively seeking bio-based packaging solutions to meet these goals. For example, companies like Cipla, Sun Pharmaceutical Industries, and Aurobindo Pharma in India are increasingly using bio-based packaging materials to meet global standards and enhance their sustainability profiles.
The major global players in the bio based packaging market include Amcor plc, Gerresheimer AG, SCHOTT Pharma, Becton, Dickinson, and Company, DS Smith, Berry Global Inc., Smurfit Kappa, Sanner GmbH, Avient Corporation, Bormioli Pharma S.p.A. and among others.
The global bio based packaging market report delivers a detailed analysis with 54 key tables, more than 44 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
LIST NOT EXHAUSTIVE